Tazemetostat - Epizyme

Drug Profile

Tazemetostat - Epizyme

Alternative Names: E-7438; EPZ-6438

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epizyme
  • Developer Eisai Co Ltd; Epizyme; Genentech; National Cancer Institute (USA)
  • Class Amines; Antineoplastics; Biphenyl compounds; Dihydropyridines; Morpholines; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour; Follicular lymphoma; Mesothelioma; Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II CNS cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Histiocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Rhabdoid tumour; Solid tumours; Synovial sarcoma
  • Phase I/II Non-small cell lung cancer
  • Phase I B cell lymphoma; Mantle-cell lymphoma

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Mantle cell lymphoma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 01 Apr 2018 Phase-II clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater, Refractory metastatic disease) in Japan (PO) (NCT03456726)
  • 16 Mar 2018 Phase-I clinical trials in B-cell lymphoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada (PO) (NCT03217253)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top